Trials / Unknown
UnknownNCT05551832
Prevalence of Marginal Ulcer After PPPD and Preventive Effect of Proton Pump Inhibitor in Korea: A Prospective Multicenter Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 360 (estimated)
- Sponsor
- Gangnam Severance Hospital · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This research is to determine which medication, Esmesol (PPI) or Placebo works best at reducing the chance that a patient will get an marginal ulcer after pancreaticoduodenectomy.
Conditions
- Pancretic Dissease (Benign/Malignancy)
- BIle Duct Diseae(Benign/Malignancy)
- Ampulla of Vater Disease (Benign/Malignancy)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arm I (Placebo), | Placebo after Pylurus preserving Pancreaticoduodenctomy (PPPD) for 6 months |
| DRUG | Arm II (ESMESOL) | SMESOL 40 mg dose administrea daily at bedtime for 6 months after PPPD , |
Timeline
- Start date
- 2022-10-10
- Primary completion
- 2023-10-01
- Completion
- 2025-05-30
- First posted
- 2022-09-23
- Last updated
- 2022-10-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05551832. Inclusion in this directory is not an endorsement.